Central nervous system cancer

Related records

Broader conditions (13)

• Cancer
• Cancer or benign tumor
• Central nervous system disorder
• Central nervous system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Human disease
• Neoplasm
• Neoplastic disease or syndrome
• Nervous system cancer
• Nervous system disorder
• Nervous system neoplasm

Narrower conditions (233)

• ACTH-producing pituitary gland carcinoma
• Adult anaplastic ependymoma
• Adult brain ependymoma
• Adult brainstem astrocytoma
• Adult brainstem glioma
• Adult brainstem gliosarcoma
• Adult brainstem mixed glioma
• Adult central nervous system choriocarcinoma
• Adult central nervous system embryonal carcinoma
• Adult central nervous system germinoma
• Adult central nervous system mixed germ cell tumor
• Adult central nervous system primitive neuroectodermal neoplasm
• Adult embryonal tumor with multilayered rosettes, c19mc-altered
• Adult glioblastoma
• Adult intracranial malignant hemangiopericytoma
• Adult leptomeningeal melanoma
• Adult malignant schwannoma
• Adult oligodendroglioma
• Adult pineoblastoma
• Adult spinal cord ependymoma

Trials (707)

• 18-F-Fluoroacetate as PET Imaging Agent
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
• 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
• 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
• A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery
• A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
• A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
• A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
• A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
• A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
• A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors
• A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
• A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects
• A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
• A Study of Avutometinib for People With Solid Tumor Cancers
• A Study of Metabolic Agents Following Brain Radiation
• A Study of Mirdametinib in People With Central Nervous System Tumors
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Approved drugs (1)

• Temozolomide

Drugs in development (87)

• 4-demethyl-4-cholesteryloxycarbonylpenclomedine Phase 2
• 6-O-benzylguanine Phase 1
• Alectinib Phase 1
• Amxt-1501 dicaprate Phase 1
• Antineoplaston A10 Phase 2
• Atezolizumab Phase 2
• Avapritinib Phase 1
• Azacitidine Phase 1
• Belvarafenib Phase 2
• Bevacizumab Phase 2
• Bortezomib Phase 1
• Busulfan Phase 2
• Cabazitaxel Phase 1
• Cabozantinib Phase 2
• Camonsertib Phase 2
• Carboplatin Phase 2
• Carmustine Phase 1
• Cediranib maleate Phase 1
• Celecoxib Phase 2
• Cemiplimab Phase 1